GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bridge Biotherapeutics Inc (XKRX:288330) » Definitions » EV-to-Revenue

Bridge Biotherapeutics (XKRX:288330) EV-to-Revenue : 1,761.06 (As of Jun. 04, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Bridge Biotherapeutics EV-to-Revenue?

EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Bridge Biotherapeutics's enterprise value is ₩19,685.14 Mil. Bridge Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 was ₩11.18 Mil. Therefore, Bridge Biotherapeutics's EV-to-Revenue for today is 1,761.06.

The historical rank and industry rank for Bridge Biotherapeutics's EV-to-Revenue or its related term are showing as below:

XKRX:288330' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.73   Med: 56.64   Max: 211253.81
Current: 1761.06

During the past 9 years, the highest EV-to-Revenue of Bridge Biotherapeutics was 211253.81. The lowest was 1.73. And the median was 56.64.

XKRX:288330's EV-to-Revenue is ranked worse than
95.78% of 996 companies
in the Biotechnology industry
Industry Median: 7.385 vs XKRX:288330: 1761.06

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

As of today (2025-06-04), Bridge Biotherapeutics's stock price is ₩734.00. Bridge Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 was ₩0.24. Therefore, Bridge Biotherapeutics's PS Ratio for today is 3,020.58.


Bridge Biotherapeutics EV-to-Revenue Historical Data

The historical data trend for Bridge Biotherapeutics's EV-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bridge Biotherapeutics EV-to-Revenue Chart

Bridge Biotherapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EV-to-Revenue
Get a 7-Day Free Trial Premium Member Only 34.94 123.14 61.14 610.56 71,817.29

Bridge Biotherapeutics Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
EV-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,170.01 - 148,543.23 71,817.29 31,037.76

Competitive Comparison of Bridge Biotherapeutics's EV-to-Revenue

For the Biotechnology subindustry, Bridge Biotherapeutics's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bridge Biotherapeutics's EV-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bridge Biotherapeutics's EV-to-Revenue distribution charts can be found below:

* The bar in red indicates where Bridge Biotherapeutics's EV-to-Revenue falls into.


;
;

Bridge Biotherapeutics EV-to-Revenue Calculation

EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.

Bridge Biotherapeutics's EV-to-Revenue for today is calculated as:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=19685.136/11.178
=1,761.06

Bridge Biotherapeutics's current Enterprise Value is ₩19,685.14 Mil.
Bridge Biotherapeutics's Revenue for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩11.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bridge Biotherapeutics  (XKRX:288330) EV-to-Revenue Explanation

The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.

Bridge Biotherapeutics's PS Ratiofor today is calculated as:

PS Ratio=Share Price (Today)/Revenue per Share (TTM)
=734.00/0.243
=3,020.58

Bridge Biotherapeutics's share price for today is ₩734.00.
Bridge Biotherapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩0.24.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Bridge Biotherapeutics EV-to-Revenue Related Terms

Thank you for viewing the detailed overview of Bridge Biotherapeutics's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Bridge Biotherapeutics Business Description

Traded in Other Exchanges
N/A
Address
58, Pangyo - ro, Gyeonggi No. 303, 255 beongil Seas Tower in Bundang Pangyo, Seongnam-si, KOR, 13486
Bridge Biotherapeutics Inc is a drug research and development company. It operates in the pharmaceutical and bio industry. The company has two pipeline clinical-stage products namely, BBT-401 and BBT-877.

Bridge Biotherapeutics Headlines

No Headlines